These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1179 related articles for article (PubMed ID: 16187913)

  • 1. Sensitive thyrotropin and thyrotropin-receptor antibody determinations one month after discontinuation of antithyroid drug treatment as predictors of relapse in Graves' disease.
    Quadbeck B; Hoermann R; Roggenbuck U; Hahn S; Mann K; Janssen OE;
    Thyroid; 2005 Sep; 15(9):1047-54. PubMed ID: 16187913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of smoking on the course of Graves' disease after withdrawal of antithyroid drugs.
    Quadbeck B; Roggenbuck U; Janssen OE; Hahn S; Mann K; Hoermann R;
    Exp Clin Endocrinol Diabetes; 2006 Sep; 114(8):406-11. PubMed ID: 17039420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Binding, stimulating and blocking TSH receptor antibodies to the thyrotropin receptor as predictors of relapse of Graves' disease after withdrawal of antithyroid treatment.
    Quadbeck B; Hoermann R; Hahn S; Roggenbuck U; Mann K; Janssen OE
    Horm Metab Res; 2005 Dec; 37(12):745-50. PubMed ID: 16372228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of remission or relapse for Graves' hyperthyroidism by the combined determination of stimulating, blocking and binding TSH-receptor antibodies after the withdrawal of antithyroid drug treatment.
    Wallaschofski H; Miehle K; Mayer A; Tuschy U; Hentschel B; Paschke R
    Horm Metab Res; 2002 Jul; 34(7):383-8. PubMed ID: 12189586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum thyrotropin receptor antibodies concentrations in patients with Graves' disease before, at the end of methimazole treatment, and after drug withdrawal: evidence that the activity of thyrotropin receptor antibody and/or thyroid response modify during the observation period.
    Carella C; Mazziotti G; Sorvillo F; Piscopo M; Cioffi M; Pilla P; Nersita R; Iorio S; Amato G; Braverman LE; Roti E
    Thyroid; 2006 Mar; 16(3):295-302. PubMed ID: 16571093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Levels of autoantibodies against human TSH receptor predict relapse of hyperthyroidism in Graves' disease.
    Schott M; Morgenthaler NG; Fritzen R; Feldkamp J; Willenberg HS; Scherbaum WA; Seissler J
    Horm Metab Res; 2004 Feb; 36(2):92-6. PubMed ID: 15002058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical features of patients with Graves' disease undergoing remission after antithyroid drug treatment.
    Vitti P; Rago T; Chiovato L; Pallini S; Santini F; Fiore E; Rocchi R; Martino E; Pinchera A
    Thyroid; 1997 Jun; 7(3):369-75. PubMed ID: 9226205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical value of a new TSH binding inihibitory activity assay using human TSH receptors in the follow-up of antithyroid drug treated Graves' disease. Comparison with thyroid stimulating antibody bioassay.
    Maugendre D; Massart C
    Clin Endocrinol (Oxf); 2001 Jan; 54(1):89-96. PubMed ID: 11167931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relapse of Graves' disease after successful outcome of antithyroid drug therapy: results of a prospective randomized study on the use of levothyroxine.
    Hoermann R; Quadbeck B; Roggenbuck U; Szabolcs I; Pfeilschifter J; Meng W; Reschke K; Hackenberg K; Dettmann J; Prehn B; Hirche H; Mann K;
    Thyroid; 2002 Dec; 12(12):1119-28. PubMed ID: 12593726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of the 2nd generation TRAK human assay did not improve prediction of relapse after antithyroid medical therapy of Graves' disease.
    Zimmermann-Belsing T; Nygaard B; Rasmussen AK; Feldt-Rasmussen U
    Eur J Endocrinol; 2002 Feb; 146(2):173-7. PubMed ID: 11834425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical value of M22-based assays for TSH-receptor antibody (TRAb) in the follow-up of antithyroid drug treated Graves' disease: comparison with the second generation human TRAb assay.
    Massart C; Gibassier J; d'Herbomez M
    Clin Chim Acta; 2009 Sep; 407(1-2):62-6. PubMed ID: 19576193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Usefulness of the 2nd generation assay for anti-TSH receptor antibodies to differentiate relapse of Graves' thyrotoxicosis from development of painless thyroiditis after antithyroid drug treatment for Graves' disease.
    Izumi Y; Takeoka K; Amino N
    Endocr J; 2005 Aug; 52(4):493-7. PubMed ID: 16127219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of l-thyroxine administration, TSH-receptor antibodies and smoking on the risk of recurrence in Graves' hyperthyroidism treated with antithyroid drugs: a double-blind prospective randomized study.
    Glinoer D; de Nayer P; Bex M;
    Eur J Endocrinol; 2001 May; 144(5):475-83. PubMed ID: 11331213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thyrotropin Receptor Antibody Levels at Diagnosis and After Thionamide Course Predict Graves' Disease Relapse.
    Tun NN; Beckett G; Zammitt NN; Strachan MW; Seckl JR; Gibb FW
    Thyroid; 2016 Aug; 26(8):1004-9. PubMed ID: 27266892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thyroid-stimulating antibody and TSH-binding inhibitor immunoglobulin in 277 Graves' patients and in 686 normal subjects.
    Takasu N; Oshiro C; Akamine H; Komiya I; Nagata A; Sato Y; Yoshimura H; Ito K
    J Endocrinol Invest; 1997 Sep; 20(8):452-61. PubMed ID: 9364248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Remission of Graves' hyperthyroidism predicted by smooth decreases of thyroid-stimulating antibody and thyrotropin-binding inhibitor immunoglobulin during antithyroid drug treatment.
    Takasu N; Yamashiro K; Komiya I; Ochi Y; Sato Y; Nagata A
    Thyroid; 2000 Oct; 10(10):891-6. PubMed ID: 11081255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Antibodies against TSH receptors (TRAb) as indicators in prognosing the effectiveness of Tiamazol therapy for Grave's Disease].
    Bojarska-Szmygin A; Ciechanek R
    Wiad Lek; 2003; 56(7-8):303-7. PubMed ID: 14969154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Individual outcome monitoring of TSH receptor antibody level for predicting the prognosis of Graves' disease].
    Rink T; Holle LH; Schroth HJ; Garth H
    Nuklearmedizin; 1998 May; 37(3):90-4. PubMed ID: 9604228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TSH receptor antibody measurements and prediction of remission in Graves' disease patients treated with minimum maintenance doses of antithyroid drugs.
    Okamoto Y; Tanigawa S; Ishikawa K; Hamada N
    Endocr J; 2006 Aug; 53(4):467-72. PubMed ID: 16820704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of thyrotropin receptor antibodies (TRAb) in Graves' disease: a 120 months prospective study.
    Cappelli C; Gandossi E; Castellano M; Pizzocaro C; Agosti B; Delbarba A; Pirola I; De Martino E; Rosei EA
    Endocr J; 2007 Dec; 54(5):713-20. PubMed ID: 17675761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 59.